Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document a foreign private issuer reporting on Form 6-K and incorporating selected reports by reference into Form F-3 and Form S-8 registration statements. Recent disclosures cover shareholder communications, strategic direction, shareholder meeting results, proxy voting matters, registration-statement references, and governance records.
The filings also describe company activity across its medical business and newer technology initiatives, including the INSPIRA™ ART100 life-support platform, the HYLA™ blood sensor, an Additively Manufactured Electronics platform branded QTREX, and quantum-connectivity applications such as cryogenic interconnect structures for superconducting quantum systems. Formal reports include material agreements, purchase-order disclosures, capital-structure context, and risk-related business updates tied to these operating areas.
IINN reported proposed sales under a Form 144 for Ordinary Shares by Yafit Tehila Hatidhar. The filing lists two proposed dispositions of 30,000 shares on 05/27/2026 for $60,561.18 and 30,000 shares on 05/28/2026 for $83,400.00.
The record also shows prior issuances upon RSU vesting of 86,395 shares on 11/02/2021 and 160,000 shares on 02/05/2024, and a listed outstanding figure of 35,949,247 shares as of 05/29/2026.
IINN reported proposed sales under a Form 144 for Ordinary Shares by Yafit Tehila Hatidhar. The filing lists two proposed dispositions of 30,000 shares on 05/27/2026 for $60,561.18 and 30,000 shares on 05/28/2026 for $83,400.00.
The record also shows prior issuances upon RSU vesting of 86,395 shares on 11/02/2021 and 160,000 shares on 02/05/2024, and a listed outstanding figure of 35,949,247 shares as of 05/29/2026.
QTREX Quantum Ltd. Chief Financial Officer Tehila Yafit reported open-market sales of a total of 60,000 Ordinary Shares of QTEX at prices between $2.0134 and $3.00 per share. Following these transactions, she directly holds 900,000 Ordinary Shares.
On the same dates, she exercised employee share options covering 13,605 Ordinary Shares at a conversion price of $0.12 per share, with no derivative options remaining after the exercise. The sales were executed pursuant to an existing Rule 10b5-1 trading plan, indicating they were pre-arranged rather than timed discretionarily.
QTREX Quantum Ltd. Chief Financial Officer Tehila Yafit reported open-market sales of a total of 60,000 Ordinary Shares of QTEX at prices between $2.0134 and $3.00 per share. Following these transactions, she directly holds 900,000 Ordinary Shares.
On the same dates, she exercised employee share options covering 13,605 Ordinary Shares at a conversion price of $0.12 per share, with no derivative options remaining after the exercise. The sales were executed pursuant to an existing Rule 10b5-1 trading plan, indicating they were pre-arranged rather than timed discretionarily.
Yafit Tehila reported a proposed sale of 30,000 Ordinary Shares. The filing shows a sale date of 05/27/2026 for 30,000 shares with proceeds listed as $60,561.18.
The record also notes 86,395 shares issued upon vesting of RSUs on 11/02/2021. The notice was submitted using broker-dealer Oppenheimer & Co. Inc.
Yafit Tehila reported a proposed sale of 30,000 Ordinary Shares. The filing shows a sale date of 05/27/2026 for 30,000 shares with proceeds listed as $60,561.18.
The record also notes 86,395 shares issued upon vesting of RSUs on 11/02/2021. The notice was submitted using broker-dealer Oppenheimer & Co. Inc.
Quantum Ltd. submitted a Form 144 notice for the proposed sale of 30,000 Ordinary Shares through Oppenheimer & Co. Inc. on 05/27/2026 on Nasdaq. The filing lists prior acquisitions including 13,605 shares acquired upon exercise of employee stock options on 05/27/2026 (cash payment upon exercise) and 86,395 shares issued upon vesting of RSUs on 11/02/2021.
Quantum Ltd. submitted a Form 144 notice for the proposed sale of 30,000 Ordinary Shares through Oppenheimer & Co. Inc. on 05/27/2026 on Nasdaq. The filing lists prior acquisitions including 13,605 shares acquired upon exercise of employee stock options on 05/27/2026 (cash payment upon exercise) and 86,395 shares issued upon vesting of RSUs on 11/02/2021.
Inspira Technologies Oxy B.H.N. Ltd. furnished a report highlighting a new commercial milestone for its ART100 system. NYU Langone Hospital in New York City issued a $580,000 purchase order for Inspira’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The evaluation involved using ART100 in the treatment of more than 30 patients across varied cardiopulmonary and surgical cases, giving NYU Langone operational experience with the platform and leading to its decision to move from clinical assessment to commercial procurement. Inspira notes that this order provides an important hospital reference as it continues commercial discussions with additional U.S. and international hospitals and pursues an active strategic process involving potential transactions related to the ART100 system and other medical assets.
Inspira Technologies Oxy B.H.N. Ltd. furnished a report highlighting a new commercial milestone for its ART100 system. NYU Langone Hospital in New York City issued a $580,000 purchase order for Inspira’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The evaluation involved using ART100 in the treatment of more than 30 patients across varied cardiopulmonary and surgical cases, giving NYU Langone operational experience with the platform and leading to its decision to move from clinical assessment to commercial procurement. Inspira notes that this order provides an important hospital reference as it continues commercial discussions with additional U.S. and international hospitals and pursues an active strategic process involving potential transactions related to the ART100 system and other medical assets.
Inspira Technologies OXY B.H.N. Ltd files an amendment to its Schedule 13G/A reporting that Joe Ronen Hayon beneficially owns 2,544,474 ordinary shares, equal to 5.7% of the company's outstanding ordinary shares. The filing states the ownership comprises 656,081 ordinary shares and 1,888,393 ordinary shares vested pursuant to issued and outstanding restricted stock units. The percentage is calculated on 44,473,260 outstanding shares. The signature block shows the amendment was signed on 05/15/2026.
Inspira Technologies OXY B.H.N. Ltd files an amendment to its Schedule 13G/A reporting that Joe Ronen Hayon beneficially owns 2,544,474 ordinary shares, equal to 5.7% of the company's outstanding ordinary shares. The filing states the ownership comprises 656,081 ordinary shares and 1,888,393 ordinary shares vested pursuant to issued and outstanding restricted stock units. The percentage is calculated on 44,473,260 outstanding shares. The signature block shows the amendment was signed on 05/15/2026.
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 4,343,252 ordinary shares, representing 9.99% of the outstanding ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 4,343,252 ordinary shares, representing 9.99% of the outstanding ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
Inspira Technologies is reshaping its strategy around three value tracks: a commercially active Additively Manufactured Electronics (AME) platform, a focused quantum connectivity program, and a repositioned medical business. Management expects recent commercial activity to mark the start of a broader revenue ramp supported by AME system sales, recurring consumables and service revenues, and monetization of medical technologies.
The Company reports more than $1 million from recent AME-related transactions, with most already received in cash, early deployments at a Tier-1 U.S. defense customer and a “Magnificent Seven” technology company, and a joint development agreement with Qarakal Quantum to validate its monolithic quantum connectivity architecture. The medical segment is being prepared for partial sale, backed by FDA-cleared ART100 usage in over 40 patients and planned FDA submission for the HYLA platform, with a goal of reaching at least a term sheet by the end of the third quarter of 2026.
Inspira is also moving to change its name to QTREX Quantum Ltd., has reduced medical business burn, terminated its ATM and SEPA facilities in March 2026, and emphasizes disciplined capital allocation aimed at preserving cash, extending runway, and translating strategic progress into measurable financial results.
Inspira Technologies is reshaping its strategy around three value tracks: a commercially active Additively Manufactured Electronics (AME) platform, a focused quantum connectivity program, and a repositioned medical business. Management expects recent commercial activity to mark the start of a broader revenue ramp supported by AME system sales, recurring consumables and service revenues, and monetization of medical technologies.
The Company reports more than $1 million from recent AME-related transactions, with most already received in cash, early deployments at a Tier-1 U.S. defense customer and a “Magnificent Seven” technology company, and a joint development agreement with Qarakal Quantum to validate its monolithic quantum connectivity architecture. The medical segment is being prepared for partial sale, backed by FDA-cleared ART100 usage in over 40 patients and planned FDA submission for the HYLA platform, with a goal of reaching at least a term sheet by the end of the third quarter of 2026.
Inspira is also moving to change its name to QTREX Quantum Ltd., has reduced medical business burn, terminated its ATM and SEPA facilities in March 2026, and emphasizes disciplined capital allocation aimed at preserving cash, extending runway, and translating strategic progress into measurable financial results.
Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on May 6, 2026. The meeting was initially adjourned at 12:00 p.m. Israel time for lack of quorum but reconvened at 1:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders approved the single agenda item described in the company’s earlier notice and proxy statement filed on April 16, 2026. The company also states that this report is incorporated by reference into its existing registration statements on Forms F-3 and S-8.
Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on May 6, 2026. The meeting was initially adjourned at 12:00 p.m. Israel time for lack of quorum but reconvened at 1:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders approved the single agenda item described in the company’s earlier notice and proxy statement filed on April 16, 2026. The company also states that this report is incorporated by reference into its existing registration statements on Forms F-3 and S-8.
Inspira Technologies OXY B.H.N. Ltd. entered a Joint Development Agreement with Qarakal Quantum, a superconducting quantum computing company, to develop and test cryogenic interconnect solutions for quantum systems. The collaboration uses Inspira’s QTREX Additively Manufactured Electronics platform inside Qarakal’s superconducting quantum environment.
The agreement sets a structured, multi-phase engineering program in which Qarakal defines technical requirements and success metrics, while Inspira supplies 3D‑printed conductive and insulating structures for evaluation at milli‑Kelvin temperatures. This initiative marks a strategic expansion of Inspira’s quantum connectivity business alongside its existing respiratory support and blood monitoring medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. entered a Joint Development Agreement with Qarakal Quantum, a superconducting quantum computing company, to develop and test cryogenic interconnect solutions for quantum systems. The collaboration uses Inspira’s QTREX Additively Manufactured Electronics platform inside Qarakal’s superconducting quantum environment.
The agreement sets a structured, multi-phase engineering program in which Qarakal defines technical requirements and success metrics, while Inspira supplies 3D‑printed conductive and insulating structures for evaluation at milli‑Kelvin temperatures. This initiative marks a strategic expansion of Inspira’s quantum connectivity business alongside its existing respiratory support and blood monitoring medical technology portfolio.